Drug Trial Radar · NCT03007147
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
352
Actual
Start
Aug 8, 2017
Primary completion
Jun 30, 2026
Study completion Sep 30, 2034
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Universita degli Studi di Milano-Bicocca
- First posted
- Jan 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
Conditions
- Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia
- T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell TransplantationProcedure
Undergo HSCT
Calaspargase PegolDrug
Given IV
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IV, SC, or IT
Daunorubicin HydrochlorideDrug
Given IV
DexamethasoneDrug
Given PO or IV
Dexrazoxane HydrochlorideDrug
Given IV
DoxorubicinDrug
Given IV
EtoposideDrug
Given IV
FilgrastimBiological
Given SC or IV
IfosfamideDrug
Given IV
Imatinib MesylateDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
Leucovorin CalciumDrug
Given PO or IV
LevoleucovorinDrug
Given PO or IV
MercaptopurineDrug
Given PO
MercaptopurineDrug
Given PO
MethotrexateDrug
Given IT
MethylprednisoloneDrug
Given IV
PegaspargaseDrug
Given IV
PrednisoloneDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Therapeutic HydrocortisoneDrug
Given IT
ThioguanineDrug
Given PO
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)Time frame: Up to 3 years
Locations
226 sites in 19 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
Palms West Radiation Therapy
Loxahatchee Groves, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Nicklaus Children's Hospital
Miami, Florida
Miami Cancer Institute
Miami, Florida
AdventHealth Orlando
Orlando, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.